Hot off the press 🔥: a new MS drug in clinical trial -- one of the BTK inhibitors, Evobrutinib -- released it's initial results.

Researchers compared this new drug against Aubagio (an older MS drug) to see which drug slowed the frequency of relapses in MS...

...ideally hoping the new drug would outperform the older drug 💊.

Unfortunately, results showed that there was no difference between the two, meaning the new drug was negative for reducing relapse rates more than Aubagio in MS.

This was a BIG shock to researchers & neurologists 😳 -- there was really high hope that this new class of drugs (BTK-inhibitors) would work better than older drugs for MS.

And honestly... Aubagio tested way better than researchers thought it would, which might pose the question of "is Aubagio more effective than we thought it was?"

There’s still hope that this new drug — and others in its class — will have other positive effects on MS like slowing the rate of disability 🚶‍♀️, but this BTK inhibitor in particular did not show a benefit on reducing relapse rates.

But… on the plus side... there are other BTK-inhibitors in clinical trial and there is still a lot of hope that they'll show better results, indicating a new class of therapeutic drug to help slow the relapses for MS.

Are you taking a disease modifying therapy (DMT)? If so… which one? ⬇️ comment below!

свернуть